Remove 2004 Remove Competition Remove Sales
article thumbnail

What Is Sports Medicine Medical Sales With Jordan Rawlins

Evolve Your Success

There is no one way when it comes to medical sales. How do you break into this field as a medical sales representative and succeed? What are the different roles in sports medicine medical sales and what do you need to prepare to ensure success in this space? It is ripe with opportunities along with a variety of paths.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Boston is emerging as one of the hottest startup cities in the country, which is great news for sales professionals. These companies are all backed by venture capital and are currently hiring in sales roles. This is by no means an exhaustive list, but here are some great companies to consider for your next sales job. ProfitWell.

Sales 76
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

Meulenbelt highlighted “the desire to have broader launches is very good,” since under the current model, if OMP companies can make a major part of their sales in a limited number of markets they are unlikely to launch elsewhere, limiting patient access. Maarten has significant competition law experience in a variety of sectors.

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Conducting internal pre-sale checks and looking at your level of compliance and licenses is a vital exercise. She joined NSF in 2017.

Pharma 119
article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings. However, new MS drugs like Novartis ’ Gilenya, were going to soon enter the market and increase competition within the MS therapeutic landscape.

article thumbnail

Reality Bites: Disappointment in the R&D Sector

Pharmaceutical Technology

As the blockbuster drugs of the 90s that earned the industry billions reach their patent shelf lives, pharmaceutical companies require new medicines to sustain an estimated $157bn worth of sales. Even so, current figures show firms’ biggest portion of spend is still on marketing and administration at 33.1%,

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Throughout 2022, Novartis was at the opposing ends of legal cases.